骶神经调控术和胫后神经电刺激治疗非神经源性下尿路功能障碍的研究进展

曹德宏; 吴康; 李金泽; 黄引; 柳良仁; 艾建忠; 魏强

doi:10.13201/j.issn.1001-1420.2022.08.014

骶神经调控术和胫后神经电刺激治疗非神经源性下尿路功能障碍的研究进展

- 四川大学华西医院泌尿外科/泌尿外科研究所(成都，610041)
基金项目:
国家自然科学基金(No：82000721)；四川省卫健委课题(No：20PJ036)

详细信息

通讯作者: 艾建忠，E-mail: ajz6363@126.com

中图分类号: R695

收稿日期: 2021-09-19

刊出日期: 2022-08-06

Research progress of sacral and percutaneous tibial neuromodulation in the treatment of non-neurogenic lower urinary tract dysfunction

- Department of Urology, Institution of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China

More Information

Corresponding author: AI Jianzhong, E-mail: ajz6363@126.com

Received Date: 19 September 2021

Publish Date: 06 August 2022

摘要

摘要: 下尿路功能障碍(LUTD)是以尿频、尿急、尿失禁、尿潴留、排尿困难等为主要临床表现的常见临床疾病并发症，严重影响患者的生活质量。药物和手术作为LUTD的传统治疗方法对难治性LUTD疗效欠佳。近年来，生物反馈电刺激疗法作为一种可选的治疗方法，在对保守治疗无效的非神经源性LUTD的治疗中，取得了良好效果。本文通过对骶神经调控术和胫后神经电刺激治疗非神经源性LUTD的研究进展进行综述，为非神经源性LUTD的治疗提供依据。
- 非神经源性下尿路功能障碍 /
- 骶神经调控术 /
- 胫后神经电刺激
Abstract: Lower urinary tract dysfunction (LUTD) is a common clinical complication characterized by frequent urination, urgent urination, incontinence, retention of urine and dysuria, which seriously affects the quality of life of the patients. As traditional treatments of LUTD, drugs and surgery are not effective in the treatment of refractory LUTD. In recent years, as an optional therapy, biofeedback electrical stimulation therapy has achieved good results in the treatment of non-neurogenic LUTD which is not effective in conservative treatment. This article reviews the research progress of sacral nerve and posterior tibial nerve in the treatment of non-neurogenic LUTD, and provides the basis for the treatment of non-neurogenic LUTD.
- non-neurogenic lower urinary tract dysfunction /
- sacral neuromodulation /
- posterior tibial neuromodulation

HTML全文

参考文献(25)

[1]	Iguchi N, Carrasco A Jr, Xie AX, et al. Functional constipation induces bladder overactivity associated with upregulations of Htr2 and Trpv2 pathways[J]. Sci Rep, 2021, 11(1): 1149. doi: 10.1038/s41598-020-80794-0
[2]	Beaumont T. Prevalence and outcome of postpartum urinary retention at an Australian hospital[J]. Midwifery, 2019, 70: 92-99. doi: 10.1016/j.midw.2018.12.013
[3]	Przydacz M, Dudek P, Chlosta P. Prevalence, bother and treatment behavior related to lower urinary tract symptoms and overactive bladder among cardiology patients[J]. J Clin Med, 2020, 9(12): 4102. doi: 10.3390/jcm9124102
[4]	Lee WC, Tain YL, Wu KL, et al. Maternal Fructose Exposure Programs Metabolic Syndrome-Associated Bladder Overactivity in Young Adult Offspring[J]. Sci Rep, 2016, 6: 34669. doi: 10.1038/srep34669
[5]	Nambiar AK, Bosch R, Cruz F, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence[J]. Eur Urol, 2018, 73(4): 596-609. doi: 10.1016/j.eururo.2017.12.031
[6]	Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society[J]. Urology, 2003, 61(1): 37-49. doi: 10.1016/S0090-4295(02)02243-4
[7]	Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder[J]. Neurourol Urodyn, 2015, 34(3): 224-230. doi: 10.1002/nau.22544
[8]	Engeler DS, Baranowski AP, Dinis-Oliveira P, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development[J]. Eur Urol, 2013, 64(3): 431-439. doi: 10.1016/j.eururo.2013.04.035
[9]	Cui Z, Wang Z, Ye G, et al. A novel three-dimensional printed guiding device for electrode implantation of sacral neuromodulation[J]. Colorectal Dis, 2018, 20(1): 26-29. doi: 10.1111/codi.13807
[10]	Steele S. Sacral nerve stimulation: 50 years in the making[J]. Can Urol Assoc J, 2012, 6(4): 231-232. doi: 10.5489/cuaj.12194
[11]	Liberman D, Ehlert MJ, Siegel SW. Sacral Neuromodulation in Urological Practice[J]. Urology, 2017, 99: 14-22. doi: 10.1016/j.urology.2016.06.004
[12]	Spinelli M, Sievert KD. Latest technologic and surgical developments in using InterStim therapy for sacral neuromodulation: im-pact on treatment success andsafety[J]. Eur Urol, 2008, 54(6): 1287-1296. doi: 10.1016/j.eururo.2008.01.076
[13]	Peeters K, Sahai A, De Ridder D, et al. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction[J]. BJU Int, 2014, 113(5): 789-794. doi: 10.1111/bju.12571
[14]	Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature[J]. Eur Urol, 2018, 73(3): 406-418. doi: 10.1016/j.eururo.2017.11.002
[15]	van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study[J]. J Urol, 2007, 178(5): 2029-2034. doi: 10.1016/j.juro.2007.07.032
[16]	Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age[J]. Urology, 2011, 77(5): 1081-1087. doi: 10.1016/j.urology.2010.08.039
[17]	Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and Treatment of Overactive Bladder(Non-Neurogenic)in Adults: AUA/SUFU Guideline Amendment 2019[J]. J Urol, 2019, 202(3): 558-563. doi: 10.1097/JU.0000000000000309
[18]	Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience[J]. BJU Int, 2012, 110(11): 176-174.
[19]	Weil EH, RuizCerdá JL, Eerdmans PH, et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial[J]. Eur Urol, 2000, 37(2): 161-171. doi: 10.1159/000020134
[20]	Hassouna MM, Siegel SW, Nÿeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety[J]. J Urol, 2000, 163(6): 1849-1854. doi: 10.1016/S0022-5347(05)67558-1
[21]	Peters KM, Killinger KA, Gilleran JP, et al. Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients[J]. Neurourol Urodyn, 2017, 36(2): 354-359. doi: 10.1002/nau.22929
[22]	Finazzi-Agrò E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial[J]. J Urol, 2010, 184(5): 2001-2006. doi: 10.1016/j.juro.2010.06.113
[23]	D'Agostino G, Condino AM, Calvi V, et al. Purinergic P2X3 heteroreceptors enhance parasympathetic motor drive in isolated porcine detrusor, a reliable model for development of P2X selective blockers for detrusor hyperactivity[J]. Pharmacol Res, 2012, 65(1): 129-136. doi: 10.1016/j.phrs.2011.10.002
[24]	Vandoninck V, van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of idiopathic nonobstructive voiding dysfunction[J]. Urology, 2003, 61(3): 567-572. doi: 10.1016/S0090-4295(02)02378-6
[25]	van Balken MR, Vandoninck V, Gisolf KW, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction[J]. J Urol, 2001, 166(3): 914-918.